Peptide-Drug Conjugates
Explore peptide research and guides on peptide-drug conjugates.
PDCs vs Antibody-Drug Conjugates Compared
Peptide-drug conjugates offer deeper tumor penetration, lower immunogenicity, and simpler manufacturing than ADCs. Here's how the two platforms compare.
Peptide-Drug ConjugatesPDC Linker Chemistry: How the Connection Matters
Peptide-drug conjugate linker chemistry explained: cleavable vs non-cleavable linkers, enzyme-sensitive release, pH triggers, and clinical design strategies.
Peptide-Drug ConjugatesPeptide-Drug Conjugates for Cancer
Peptide-drug conjugates deliver cytotoxic payloads directly to tumors using receptor-targeting peptides. Here is what the clinical evidence shows so far.
Peptide-Drug ConjugatesRGD Peptide-Drug Conjugates for Tumor-Targeted Chemotherapy
How RGD peptides deliver chemotherapy to tumors via integrin receptors. Covers clinical trials, linker chemistry, iRGD penetration, and immunotherapy combos.
Peptide-Drug ConjugatesSomatostatin PDCs: Hormone Receptors as Drug Addresses
Somatostatin receptor targeting delivers radiation directly to neuroendocrine tumors. From Lutathera to next-gen alpha emitters, this is the PDC frontier.